Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03835429 · ClinicalTrials.gov registry record · NA
Effect of Oral Appliance Therapy on Atrial Fibrillation
A NA study, sponsored by Texas A&M University.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT03835429: Clinical Trial NA study, sponsored by Texas A&M University.
NCT03835429 is a NA study that was terminated before completion, run by Texas A&M University. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03835429, a NA study, was terminated before completion, sponsored by Texas A&M University.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot study is expected to determine the efficacy of using the midline traction designed MyTAP plus mouth shield (MyTAP + MS) oral appliance combination in decreasing the number of Atrial Fibrillation events. The MS is a patient comfort accessory to the MyTAP.
Primary Outcome
Measured (%) incidence of paroxysmal AF episodes \>10 seconds in duration, 1-month after starting OA (T1) therapy compared with 1-month prior to using OA.
Interventions
- DEVICE MyTAP oral appliance plus mouth shield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2025-01-03 |
| Phase | NA |
Why NCT03835429 stopped before completion
NCT03835429 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which MyTAP oral appliance plus mouth shield is the first listed.
NCT03835429 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03835429 about?
NCT03835429 is a clinical study titled "Effect of Oral Appliance Therapy on Atrial Fibrillation". This pilot study is expected to determine the efficacy of using the midline traction designed MyTAP plus mouth shield (MyTAP + MS) oral appliance combination in decreasing the number of Atrial Fibrillation events. The MS is a patient comfort accessory to the MyTAP.
What is the current status of trial NCT03835429?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2019-01-15. Estimated completion is 2025-01-03.
What interventions are being tested in trial NCT03835429?
The interventions under investigation include: MyTAP oral appliance plus mouth shield (DEVICE).
Who is sponsoring clinical trial NCT03835429?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03835429's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI